Paper Details

  1. Home
  2. Paper Details

Bosutinib: a novel second-generation tyrosine kinase inhibitor.

Author: BrümmendorfTim H, IsfortSusanne, Keller-v AmsbergGunhild, KoschmiederSteffen, SchafhausenPhilippe

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Bosutinib is a new drug for treating chronic myeloid leukemia (CML) and works by inhibiting certain enzymes. It is effective for patients who are resistant or intolerant to other treatments, but may cause gastrointestinal side effects.
Paper Details　
Original Abstract of the Article :
Bosutinib (SKI-606) is a 4-anilino-3-quinoline carbonitrile, which acts as a dual inhibitor of Src and ABL kinases. In addition, the BCR-ABL fusion gene product, a constitutively activated tyrosine kinase which is crucial for the development of chronic myeloid leukemia (CML), is highly sensitive to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/978-3-642-54490-3_4

データ提供：米国国立医学図書館（NLM）

Bosutinib: A New Hope in the Desert of Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of blood cancer that can be challenging to treat. It's like a camel facing a treacherous sandstorm - a formidable foe! This research explores the potential of a new drug, bosutinib, to combat CML.

Bosutinib: A Novel Tyrosine Kinase Inhibitor

Bosutinib is a powerful tyrosine kinase inhibitor that has shown promising results in treating CML. It has been effective in patients who have not responded to traditional treatments and has even been shown to overcome resistance to other tyrosine kinase inhibitors. It's like finding a hidden oasis with a fresh spring of water in a dry desert - a potential breakthrough in CML treatment.

Hope for CML Patients

This research offers a glimmer of hope for individuals battling CML. Bosutinib's effectiveness in overcoming resistance to other treatments and its manageable side effects make it a valuable tool in the fight against this disease. This is a significant advancement in the search for effective therapies for CML, and it's a reminder that even in the harshest deserts, hope can blossom.

Dr.Camel's Conclusion

Bosutinib represents a promising new weapon in the fight against chronic myeloid leukemia. It's a beacon of hope in the desert of cancer research, offering a potential solution to overcome treatment resistance and improve patient outcomes. With continued research and development, we may one day find a cure for CML, transforming this formidable foe into a distant memory.

Date :
  1. Date Completed 2014-09-08
  2. Date Revised 2015-08-28
Further Info :

Pubmed ID

24756786

DOI: Digital Object Identifier

10.1007/978-3-642-54490-3_4

Related Literature

Article Analysis
・Side Effects of bosutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.